Skip to navigation Skip to content

Clinical Trial: Ofatumumab for Patients with Relapsing Multiple Sclerosis

Share

Details
Type of MS: RRMS|SPMS
Treatment mode of action: To affect immune function
Number of Subjects: 100
Medication: Ofatumumab
Location: California
Institutions: Lightship
3655 Lomita Blvd.,
Suite 318,
Torrance, Ca 90505
  Contact Information
Chris DiMatteo
323-403-5882
researchstudies@lightship.com

Funding:

Novartis

Description

MS study evaluating the continued effectiveness, safety and tolerability of Ofatumumab in adults, between the ages 18-60, with relapsing multiple sclerosis who are transitioning from traditional anti-CD20 therapy.

Click on this link to answer a few questions to see if you qualify for this study:  https://www.lightshipclinical.com/screener/ms?utm_source=mssociety&utm_medium=advocacy
 

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.